A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314)

Registry ID

LOXO-BTK-20030 (J2N-OX-JZNU)

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

LOXO ONCOLOGY INC

Start date

2024-02-01

Last update

2022-06-01

Conditions

• LYMPHOCYTIC LEUKEMIA

View on source registry